cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc2gmlpd
title: CCDC 2282954: Experimental Crystal Structure Determination

description: Related Article: Peter G. Jones, Matthias Freytag, Andrea Winkler, Matthias Tamm|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.23911935
title: Posture_4520_my_yolo_dataset contains 4520 images——train5

description: The Posture_4520_my_yolo_dataset contains 4520 images. According to the ratio of 8:1:1, the training set (3616), the verification set (452), the test set (452).
DOI: 10.6084/m9.figshare.23911935.v1
title: Posture_4520_my_yolo_dataset contains 4520 images——train5

description: The Posture_4520_my_yolo_dataset contains 4520 images. According to the ratio of 8:1:1, the training set (3616), the verification set (452), the test set (452).
DOI: 10.6084/m9.figshare.23866962.v29
title: Untitled Item

description: Regridding Global CMIP6 GCMs dataset(0.5 degree)Historical dataset: 7 CMIP6 GCMs (1850-2014, ACCESS-CM2 to GFDL-ESM4)Future dataset: 7 CMIP6 GCMs and 4 SSP scenarios (2015-2100)Composition of dataset: Average temperature, Maximum temperature, Minimum temperature, Windspeed, Relative humidity, Solar radiationIf you are using our codes and dataset, please use the following references:Song, Y.H., Chung, E.S., Shahid, S., Kim, Y.J., Kim, D.K. 2023. Development of global monthly dataset of CMIP6 climate variables for estimating evapotranspiration. Scientific Data.<br>
DOI: 10.18712/nsd-nsd3122-v3
title: Democratic Urban Development in the Digital Age (DEMUDIG)

description: The data was collected in connection with the DEMUDIG project which lasted from 01.07.2018-31.03.2022. The project compared citizen participation in urban development in Oslo, Madrid and Melbourne. The project was about participation and involvement, and studied how citizens and other stakeholders engaged and what the authorities did to obtain input from the population. It focused specifically on participation via websites, apps and social media. The project was also concerned with what happens to the input when the participation process is completed, and the policy is to be implemented.
DOI: 10.6084/m9.figshare.19300000
title: Cinnamaldehyde encapsulation within new natural wax-based nanoparticles; formation, optimization and characterization

description: Wax-based solid lipid nanoparticles were prepared using beeswax (BW) and propolis wax (PW) by antisolvent precipitation. Response surface methodology was applied to optimize the production condition with respect to waxes concentrations, emulsifier content (sodium caseinate and polysorbate 80) and solvent to antisolvent ratios. The formulation of wax-based nanoparticles with higher yield, lower polydispersity index and smaller particle size for each wax was used to encapsulate cinnamaldehyde (CA). The results of applying different ratios of wax: CA (1:0.25–1:3 w/w) showed that the best ratio was 1:0.25 with the smallest particle size and the highest encapsulation efficiency (EE). CA-loaded nanoparticles had spherical morphology with β’ form structure. Also, the release study confirmed a high capability of waxes to control release and desirable protection of CA. Therefore, the antisolvent precipitation is a feasible way to fabricate solid lipid nanoparticles as promising carriers for bioactive compounds with desirable properties.
DOI: 10.6084/m9.figshare.19300000.v1
title: Cinnamaldehyde encapsulation within new natural wax-based nanoparticles; formation, optimization and characterization

description: Wax-based solid lipid nanoparticles were prepared using beeswax (BW) and propolis wax (PW) by antisolvent precipitation. Response surface methodology was applied to optimize the production condition with respect to waxes concentrations, emulsifier content (sodium caseinate and polysorbate 80) and solvent to antisolvent ratios. The formulation of wax-based nanoparticles with higher yield, lower polydispersity index and smaller particle size for each wax was used to encapsulate cinnamaldehyde (CA). The results of applying different ratios of wax: CA (1:0.25–1:3 w/w) showed that the best ratio was 1:0.25 with the smallest particle size and the highest encapsulation efficiency (EE). CA-loaded nanoparticles had spherical morphology with β’ form structure. Also, the release study confirmed a high capability of waxes to control release and desirable protection of CA. Therefore, the antisolvent precipitation is a feasible way to fabricate solid lipid nanoparticles as promising carriers for bioactive compounds with desirable properties.
DOI: 10.6084/m9.figshare.19337393
title: Formulation of roselle extract water-in-oil nanoemulsion for controlled pulmonary delivery

description: The anthocyanin (ACN)-rich roselle extract has the potential to inhibit lung cancer. However, the compounds demonstrate low bioavailability and stability in biological applications. The present study proposed a stable formulation of a water-in-oil (w/o) roselle extract nanoemulsion by combining low (hot temperature inversion) and high-energy approaches (ultrasonication and ultra-homogenization) for pulmonary delivery. The stable w/o formulation comprised of roselle extract (0.04 w/w%), sodium chloride solution (3.0 w/w%), medium-chain triglyceride (81.9 w/w%), surfactant (Tween 80 and Span 80) (15.0 w/w%), hydrophilic-lipophilic balance (HLB) of 6.7 [Tween 80/Span 80 (22.5:77.5)] to yield the stable nanoemulsion.The best nanoemulsion showed an average 298 nm particle size, polydispersity index of 0.6, and zeta potential of −49.0 mV. The emulsions were stable in the centrifuge- and freeze-thaw cycle tests,-alongside the 60-days storage tests at 4 °C, 25 °C, and 35 °C. The <i>in-vitro</i> release of the roselle extract at pH 6.5 buffer was 44.7% and 40.7% at pH 7.4 (p &gt; 0.05), with the release patterns following the non-Fickian diffusion. Hence, the present study successfully developed a stable w/o roselle extract nanoemulsion with a relatively moderate release rate of the ACNs, supporting its suitability as a nanocarrier for pulmonary delivery.
DOI: 10.6084/m9.figshare.19337393.v1
title: Formulation of roselle extract water-in-oil nanoemulsion for controlled pulmonary delivery

description: The anthocyanin (ACN)-rich roselle extract has the potential to inhibit lung cancer. However, the compounds demonstrate low bioavailability and stability in biological applications. The present study proposed a stable formulation of a water-in-oil (w/o) roselle extract nanoemulsion by combining low (hot temperature inversion) and high-energy approaches (ultrasonication and ultra-homogenization) for pulmonary delivery. The stable w/o formulation comprised of roselle extract (0.04 w/w%), sodium chloride solution (3.0 w/w%), medium-chain triglyceride (81.9 w/w%), surfactant (Tween 80 and Span 80) (15.0 w/w%), hydrophilic-lipophilic balance (HLB) of 6.7 [Tween 80/Span 80 (22.5:77.5)] to yield the stable nanoemulsion.The best nanoemulsion showed an average 298 nm particle size, polydispersity index of 0.6, and zeta potential of −49.0 mV. The emulsions were stable in the centrifuge- and freeze-thaw cycle tests,-alongside the 60-days storage tests at 4 °C, 25 °C, and 35 °C. The <i>in-vitro</i> release of the roselle extract at pH 6.5 buffer was 44.7% and 40.7% at pH 7.4 (p &gt; 0.05), with the release patterns following the non-Fickian diffusion. Hence, the present study successfully developed a stable w/o roselle extract nanoemulsion with a relatively moderate release rate of the ACNs, supporting its suitability as a nanocarrier for pulmonary delivery.
DOI: 10.5281/zenodo.8229186
title: Conjunto de dados pesquisa bibliométrica História da Educação - cocitação e acomplamento bibliográfico de autores

description: Trata-se do conjunto de dados da pesquisa bibliométrica "História da Educação: acoplamento bibliográfico e análise de cocitação de autores", extraído em 7 de agosto de 2023, da base de dados Web of Science.
DOI: 10.5281/zenodo.8229185
title: Conjunto de dados pesquisa bibliométrica História da Educação - cocitação e acomplamento bibliográfico de autores

description: Trata-se do conjunto de dados da pesquisa bibliométrica "História da Educação: acoplamento bibliográfico e análise de cocitação de autores", extraído em 7 de agosto de 2023, da base de dados Web of Science.
DOI: 10.15131/shef.data.23899842
title: Supplementary data for main manuscript: Multivariable model to predict an ACTH stimulation test to diagnose adrenal insufficiency using previous test results

description: This is supplementary material to accompany main manuscript "Multivariable model to predict an ACTH stimulation test to diagnose adrenal insufficiency using previous test results".
DOI: 10.15131/shef.data.23899842.v2
title: Supplementary data for main manuscript: Multivariable model to predict an ACTH stimulation test to diagnose adrenal insufficiency using previous test results

description: This is supplementary material to accompany main manuscript "Multivariable model to predict an ACTH stimulation test to diagnose adrenal insufficiency using previous test results".
DOI: 10.15131/shef.data.23899842.v1
title: Supplementary data for main manuscript: Multivariable model to predict the result of an ACTH stimulation test (AST) to diagnose adrenal insufficiency using results of a previous AST

description: This is supplementary material to accompany main manuscript "Multivariable model to predict the result of an ACTH stimulation test (AST) to diagnose adrenal insufficiency using results of a previous AST".
DOI: 10.6084/m9.figshare.23796012
title: Saffron extract

description: Raw data from experiment
DOI: 10.6084/m9.figshare.23796012.v1
title: Saffron extract

description: Raw data from experiment
DOI: 10.6084/m9.figshare.21936555
title: EtherDiffer: Differential Testing on RPC Services of Ethereum Nodes (Data)

description: This repository contains the datasets used in evaluation of the following paper: "EtherDiffer: Differential Testing on RPC Services of Ethereum Nodes" (ESEC/FSE 2023)<b>Effectiveness of Test Case Generation:</b> <b>RQ1.tar.gz</b>3,000 semantically-valid test cases: valid_tcs/3,000 semantically-invalid test cases: invalid_tcs/Result file: tc_gen.stats<b>Deviation and Bug Detection Capability:</b> <b>RQ2.tar.gz</b>Result from a single iteration: iter-[#]/where each iter-[#]/ contains:Network configuration files for each target node: configs/Chain data directory for each target node: data/Generated test cases: testcases/Execution results from each target node: exec-resultsError and value deviations found by EtherDiffer: reports/<b>Comparison with the Official Tool:</b> <b>RQ3.tar.gz</b>Data for chain generation: chain/Data for test case generation: test_case/where chain/ contains:Generated chain from EtherDiffer: data-EtherDiffer.tar.gzGenerated chain from Hive: data-hive.tar.gzScript to extract chain data: chain.jsResult file for EtherDiffer chain: EtherDiffer_chain.statsResult file for Hive chain: hive_chain.statswhere test_case/ containsGenerated test cases from EtherDiffer: EtherDiffer/Generated test cases from Hive: hive/
DOI: 10.6084/m9.figshare.23912331
title: RandomForest classifiers

description: RandomForest classifier for PPI and H2RA group to classify samples collected before or after drug administration.
DOI: 10.18419/darus-2785
title: Stuttgart Open Relay Degradation Dataset (SOReDD)

description: Real-life industrial use cases for machine learning oftentimes involve heterogeneous and dynamic assets, processes and data, resulting in a need to continuously adapt the learning algorithm accordingly. Industrial transfer learning offers to lower the effort of such adaptation by allowing the utilization of previously acquired knowledge in solving new (variants of) tasks. Being data-driven methods, the development of industrial transfer learning algorithms naturally requires appropriate datasets for training. However, open-source datasets suitable for transfer learning training, i.e. spanning different assets, processes and data (variants), are rare. With the Stuttgart Open Relay Degradation Dataset (SOReDD) we want to offer such a dataset. It provides data on the degradation of different electromechanical relays under different operating conditions, allowing for a large number of different transfer scenarios. Although such relays themselves are usually inexpensive standard components, their failure often leads to the failure of the machine as a whole due to their role as the central power switching element of a machine. The main cost factor in the event of a relay defect is therefore not the relay itself, but the reduced machine availability. It is therefore desirable to predict relay degradation as accurately as possible for specific applications in order to be able to replace relays in good time and avoid unplanned machine downtimes. Nevertheless, data-driven failure prediction for electromechanical relays faces the challenge that relay degradation behavior is highly dependent on the operating conditions, the high-resolution measurement data on relay degradation behavior is only collected in rare cases, and these can then only cover a fraction of the possible operating environments. Relays are thus representative of many other central standard components in automation technology. For more information (especially on the specific structure and contents of this dataset), please see "2020 Stuttgart Open Relay Degradation Dataset (SOReDD).pdf".
DOI: 10.17617/4.df
title: Acidic pH Promotes Refolding and Macroscopic Assembly of Amyloid β (16–22) Peptides at the Air-Water Interface

description: Lu, H., Bellucci, L., Sun, S., Qi, D., Rosa, M., Berger, R., et al. (2022). Acidic pH Promotes Refolding and Macroscopic Assembly of Amyloid β (16–22) Peptides at the Air-Water Interface. The Journal of Physical Chemistry Letters, 13(29), 6674-6679. doi:10.1021/acs.jpclett.2c01171.
DOI: 10.5281/zenodo.8229240
title: Jbrowse multi-wiggle track issue

description: SLBP crosslink sites bigwig files Data source: ENCODE consortium SLBP eCILP datasets Bam files were downloaded and crosslink sites at the start sites were extracted and converted to bigwig files
DOI: 10.5281/zenodo.8229239
title: Jbrowse multi-wiggle track issue

description: SLBP crosslink sites bigwig files Data source: ENCODE consortium SLBP eCILP datasets Bam files were downloaded and crosslink sites at the start sites were extracted and converted to bigwig files
DOI: 10.6084/m9.figshare.23294978.v2
title: Supplementary Material for: A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial

description: Background: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, the TACTICS-L trial, investigated the efficacy and safety of TACE plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization and has a better ORR than sorafenib (jRCTs031180074). Patients and Methods: Participants were patients with HCC who had not previously received systemic therapy, hepatic arterial infusion chemotherapy, or immunotherapy, and who were ineligible for resection or percutaneous ablation therapy. LEN was to be administered 14–21 days before the first TACE, stopped 2 days before TACE, and resumed 3 days after TACE. Key inclusion criteria were unresectable HCC, Child-Pugh A liver function, 0–2 prior TACE sessions, tumor size ≤10 cm, number of tumors ≤10, and ECOG performance status 0–1. Key exclusion criteria were vascular invasion and extrahepatic spread. The primary endpoint was PFS by RECICL, and secondary endpoints were time to untreatable progression, objective response rate (ORR), OS, and safety. Results: A total of 62 HCC patients were enrolled in this trial. The median age was 72 years, 77.4% of patients were men, and 95.2% had PS 0. The primary endpoint of median PFS was 28.0 months (95% CI 25.1–31.0) after a minimum 24 months of follow-up. The secondary endpoint of median OS was not reached (95% CI 35.5 months–NR). LEN-TACE achieved a high response rate and high CR rate (4 weeks after the first TACE: ORR 79.0%, CR rate 53.2%; best response: ORR 88.7%, CR rate 67.7%) by RECICL. Exploratory subgroup analyses showed that the characteristics of responders/nonresponders (ORR and CR) were similar, and that LEN-TACE would be effective in all subgroups, including the population in whom TACE alone would be less likely to be curative (e.g., patients with the nonsimple nodular type or a high tumor burden). The relative dose intensity of LEN before the first TACE was important for achieving higher CR/ORR by LEN-TACE. No new safety concerns were observed. Conclusion: The results of this trial provide encouraging evidence supporting the efficacy and favorable safety profile of LEN-TACE in patients who are ineligible for locoregional therapy.
DOI: 10.6084/m9.figshare.23294978
title: Supplementary Material for: A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial

description: Background: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, the TACTICS-L trial, investigated the efficacy and safety of TACE plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization and has a better ORR than sorafenib (jRCTs031180074). Patients and Methods: Participants were patients with HCC who had not previously received systemic therapy, hepatic arterial infusion chemotherapy, or immunotherapy, and who were ineligible for resection or percutaneous ablation therapy. LEN was to be administered 14–21 days before the first TACE, stopped 2 days before TACE, and resumed 3 days after TACE. Key inclusion criteria were unresectable HCC, Child-Pugh A liver function, 0–2 prior TACE sessions, tumor size ≤10 cm, number of tumors ≤10, and ECOG performance status 0–1. Key exclusion criteria were vascular invasion and extrahepatic spread. The primary endpoint was PFS by RECICL, and secondary endpoints were time to untreatable progression, objective response rate (ORR), OS, and safety. Results: A total of 62 HCC patients were enrolled in this trial. The median age was 72 years, 77.4% of patients were men, and 95.2% had PS 0. The primary endpoint of median PFS was 28.0 months (95% CI 25.1–31.0) after a minimum 24 months of follow-up. The secondary endpoint of median OS was not reached (95% CI 35.5 months–NR). LEN-TACE achieved a high response rate and high CR rate (4 weeks after the first TACE: ORR 79.0%, CR rate 53.2%; best response: ORR 88.7%, CR rate 67.7%) by RECICL. Exploratory subgroup analyses showed that the characteristics of responders/nonresponders (ORR and CR) were similar, and that LEN-TACE would be effective in all subgroups, including the population in whom TACE alone would be less likely to be curative (e.g., patients with the nonsimple nodular type or a high tumor burden). The relative dose intensity of LEN before the first TACE was important for achieving higher CR/ORR by LEN-TACE. No new safety concerns were observed. Conclusion: The results of this trial provide encouraging evidence supporting the efficacy and favorable safety profile of LEN-TACE in patients who are ineligible for locoregional therapy.
DOI: 10.6084/m9.figshare.23294978.v1
title: Supplementary Material for: A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial

description: Background: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, the TACTICS-L trial, investigated the efficacy and safety of TACE plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization and has a better ORR than sorafenib (jRCTs031180074). Patients and Methods: Participants were patients with HCC who had not previously received systemic therapy, hepatic arterial infusion chemotherapy, or immunotherapy, and who were ineligible for resection or percutaneous ablation therapy. LEN was to be administered 14–21 days before the first TACE, stopped 2 days before TACE, and resumed 3 days after TACE. Key inclusion criteria were unresectable HCC, Child-Pugh A liver function, 0–2 prior TACE sessions, tumor size ≤10 cm, number of tumors ≤10, and ECOG performance status 0–1. Key exclusion criteria were vascular invasion and extrahepatic spread. The primary endpoint was PFS by RECICL, and secondary endpoints were time to untreatable progression, objective response rate (ORR), OS, and safety. Results: A total of 62 HCC patients were enrolled in this trial. The median age was 72 years, 77.4% of patients were men, and 95.2% had PS 0. The primary endpoint of median PFS was 28.0 months (95% CI 25.1–31.0) after a minimum 24 months of follow-up. The secondary endpoint of median OS was not reached (95% CI 35.5 months–NR). LEN-TACE achieved a high response rate and high CR rate (4 weeks after the first TACE: ORR 79.0%, CR rate 53.2%; best response: ORR 88.7%, CR rate 67.7%) by RECICL. Exploratory subgroup analyses showed that the characteristics of responders/nonresponders (ORR and CR) were similar, and that LEN-TACE would be effective in all subgroups, including the population in whom TACE alone would be less likely to be curative (e.g., patients with the nonsimple nodular type or a high tumor burden). The relative dose intensity of LEN before the first TACE was important for achieving higher CR/ORR by LEN-TACE. No new safety concerns were observed. Conclusion: The results of this trial provide encouraging evidence supporting the efficacy and favorable safety profile of LEN-TACE in patients who are ineligible for locoregional therapy.
DOI: 10.6084/m9.figshare.23911425
title: Subventricular Zone atlas of the human brain

description: Atlas of the subventricular zone in MNI space:Symmetric version: SVZ_mask_sym.nii.gz + SVZ_mask_sym.csv represented in the 'ICBM 2009b Nonlinear Symmetric' template with 0.5×0.5×0.5mm resolutionAsymmetric version: SVZ_mask_asym.nii.gz + SVZ_mask_asym.csv represented in the 'ICBM 2009b Nonlinear Asymmetric' template with 0.5×0.5×0.5mm resolutionThe atlas is divided into:Separate left and right sidesBoth sides have 4 subregions: Frontal Horn, Body, Occipital Horn and Temporal HornFor more details:Danique E Bruil, Szabolcs David, Steven H J Nagtegaal, Sophia F A M de Sonnaville, Joost J C Verhoeff, Irradiation of the subventricular zone and subgranular zone in high- and low-grade glioma patients: an atlas-based analysis on overall survival, Neuro-Oncology Advances, Volume 4, Issue 1, January-December 2022, vdab193, https://doi.org/10.1093/noajnl/vdab193Please cite this work when using the atlas.
DOI: 10.5523/bris.1wjyuvl4r56cy2lde94ojyfo41
title: Use of intra-oral scan images for oral hygiene advice plus anti-gingivitis toothpaste for improving gum health

description: Data from a randomised controled trial of a complex intervention comprising oral hygiene advice given with the aid of intra-oral scans of the participants mouths pre and post toothbrushing together with use of an anti-gingivitis toothpaste and motivational reminders, compared to standard oral hygiene advice as provided in general dental practice.